Bayer's new long-acting IUD Kyleena approved by the US and European markets
Kyleena, a new long-acting IUD developed by Bayer, a German pharmaceutical giant, has received good news in the US and EU regulation. In the middle of last month, Kyleena was approved by the US Food and Drug Administration (FDA); recently, Bayer announced the successful completion of the European registration process for the product in the EU. It is expected that in the coming weeks, the health departments of EU member states will continue to award Kyleena's national marketing authorization. Bayer has planned to launch Kyleena in the US market in October, and the European market is expected to be available in January 2017. Kyleena is a new long-acting IUD, a new low-dose levonorgestrel intrauterine system (LNG-IUS). LNG-IUS is one of the most effective long-acting contraceptive methods and can be removed at any time. After taking out, women can quickly return to normal fertility. Kyleena is a small, flexible, plastic T-shaped device containing 19.5 mg of the synthetic hormone levonorgestrel. The Kyleena measures 28 mm x 30 mm and has a tube diameter of 3.8 mm. Once placed in the uterus, Kyleena is able to deliver low doses of levonorgestrel for up to 5 years of contraception. China Extract Powder For Use As Dietary Supplement Extract Powder, Extract Powder Manufacturer Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.anabolicsteriod.com